Regulación europeaSalud - Farma - Biotecnología
bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
09/11/2026 06:59
AMFPublicación inmediata
Marcy l’Étoile, France – November 9th, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the BIOFIRE® FILMARRAY®
bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Marcy l’Étoile, France – November 9th, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the BIOFIRE® FILMARRAY®
Gastrointestinal 1.1 (GI1.1) Panel has obtained U.S Food and Drug Administration
(FDA) 510(k) clearance and IVDR1 CE marking, and the BIOFIRE® FILMARRAY®
Gastrointestinal 1.1 (GI1.1) Panel Mid has received US FDA 510(k) clearance. These PCR* molecular panels test 22 and 11, respectively, of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in about one hour.
Acute infectious gastroenteritis remains a significant global health concern, driven by a diverse and continually evolving range of viral, bacterial, and parasitic pathogens that inflame the gastrointestinal tract. Clinical manifestations such as diarrhea, vomiting, fever, and abdominal pain are often nonspecific, making diagnostic testing even more critical. The highest disease burden affects young children, older adults, and immunocompromised individuals. Diarrheal diseases, which cause an estimated 1.7 billion cases worldwide each year.2 continue to rank among the leading causes of mortality in children under 60 months of age.
As pathogen populations shift over time through genetic variation, emergence of new strains, and changes in epidemiological patterns, diagnostic technologies must evolve to ensure accurate detection, timely clinical decision-making, and effective public health responses.
Redesigned norovirus assay and improved Campylobacter detection
In line with its commitment to continuous improvements and to delivering high-quality diagnostic solutions, bioMérieux has developed the BIOFIRE® FILMARRAY® GI1.1 Panel and BIOFIRE® FILMARRAY® GI1.1 Panel Mid. These new versions include a redesigned norovirus GI/GII assay and a software-based improvement for
Campylobacter detection, further strengthening the panels’ specificity and providing greater confidence in every result.
These molecular syndromic testing solutions are capable of simultaneously detecting 22 and 11 pathogens*, respectively, directly from stool samples of individuals presenting with signs and/or symptoms of gastrointestinal infection. Designed for use on bioMérieux’s BIOFIRE® FILMARRAY® 2.0 and TORCH systems, they require about two minutes of hands-on time for setup, with an approximate run time of about one hour.
Helping clinicians make informed decisions